MCID: ACT135
MIFTS: 57

Acute Graft Versus Host Disease

Categories: Rare diseases, Genetic diseases, Blood diseases

Aliases & Classifications for Acute Graft Versus Host Disease

MalaCards integrated aliases for Acute Graft Versus Host Disease:

Name: Acute Graft Versus Host Disease 49 55
Acute Graft-Versus-Host Disease 51
Acute Gvh Disease 69
Acute Gvhd 49

Classifications:

Orphanet: 55  
Rare immunological diseases


External Ids:

Orphanet 55 ORPHA99920
UMLS via Orphanet 70 C0856825
ICD10 via Orphanet 33 T86.0
UMLS 69 C0856825

Summaries for Acute Graft Versus Host Disease

MalaCards based summary : Acute Graft Versus Host Disease, also known as acute graft-versus-host disease, is related to hematopoietic stem cell transplantation and chronic graft versus host disease. An important gene associated with Acute Graft Versus Host Disease is ARHGAP45 (Rho GTPase Activating Protein 45), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Tacrolimus and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Acute Graft Versus Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Acute Graft Versus Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 275)
# Related Disease Score Top Affiliating Genes
1 hematopoietic stem cell transplantation 30.9 ARHGAP45 IFNG IL10 IL2 TNF
2 chronic graft versus host disease 30.4 IFNG IL10 IL2RA
3 graft-versus-host disease 30.4 ARHGAP45 FASLG GZMB IFNG IL10 IL2
4 mouth disease 30.2 IFNG IL10 TNF
5 aspergillosis 30.1 IFNG IL10 IL4
6 allergic hypersensitivity disease 30.1 IFNG IL10 IL4
7 combined immunodeficiency, x-linked 30.0 IL2 IL2RA IL4
8 cytomegalovirus infection 29.9 IFNG IL10 IL2RA TNF
9 bronchiolitis 29.9 IFNG IL10 IL4 TNF
10 lymphopenia 29.6 FASLG IFNG IL2 IL2RA
11 bronchiolitis obliterans 29.6 GZMB IFNG IL10 TNF
12 lichen planus 29.5 GZMB IFNG IL4 TNF
13 colitis 29.1 IFNG IL10 IL2 IL4 NOD2 TNF
14 erythema multiforme 29.0 FASLG GZMB IFNG IL2 TNF
15 punctate inner choroidopathy 10.6 IL10 TNF
16 oral tuberculosis 10.5 IL2 TNF
17 variola major 10.5 IFNG IL2
18 mycoplasmal pneumonia 10.5 IFNG IL4
19 microscopic polyangiitis 10.5 IL10 TNF
20 multifocal choroiditis 10.5 IL10 TNF
21 staphylococcal toxic shock syndrome 10.5 IFNG TNF
22 berylliosis 10.5 IFNG IL2
23 transient hypogammaglobulinemia 10.5 IL10 TNF
24 sporotrichosis 10.5 IFNG IL10
25 leukemia 10.5
26 choroiditis 10.5 IL10 TNF
27 chronic beryllium disease 10.5 IFNG TNF
28 streptococcal toxic-shock syndrome 10.5 IL2 TNF
29 immunoglobulin a deficiency 1 10.5 IL10 IL4
30 virus associated hemophagocytic syndrome 10.5 IL2 IL4
31 trichosporonosis 10.5 IFNG TNF
32 b-cell growth factor 10.4 IFNG IL4
33 farmer's lung 10.4 IL2 TNF
34 systemic onset juvenile idiopathic arthritis 10.4 IL18 TNF
35 mucocutaneous leishmaniasis 10.4 IL10 TNF
36 retinitis pigmentosa 22 10.4 IL10 IL4
37 idiopathic achalasia 10.4 IL10 TNF
38 necrotizing ulcerative gingivitis 10.4 IL10 IL18
39 immune suppression 10.4 IFNG IL10 IL2
40 pouchitis 10.4 IL10 NOD2
41 chronic active epstein-barr virus infection 10.4 IFNG IL10 IL2
42 cow milk allergy 10.4 IL10 IL18
43 trichuriasis 10.4 IL10 TNF
44 herpes zoster 10.4 IFNG IL10 IL2
45 hemorrhagic fever 10.4 IFNG IL10 TNF
46 aseptic meningitis 10.4 IFNG IL10 TNF
47 spotted fever 10.4 IFNG IL10 TNF
48 autoimmune myocarditis 10.4 IFNG IL2 TNF
49 uremic pruritus 10.4 IL18 IL2
50 plasmodium vivax malaria 10.4 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Acute Graft Versus Host Disease:



Diseases related to Acute Graft Versus Host Disease

Symptoms & Phenotypes for Acute Graft Versus Host Disease

GenomeRNAi Phenotypes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 GZMB IL10 IL18 IL2 IL2RA NOD2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 GZMB IL10 IL18 IL2 IL2RA NOD2

MGI Mouse Phenotypes related to Acute Graft Versus Host Disease:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 FASLG IL18 IFNG IL2 IL10 NOD2
2 digestive/alimentary MP:0005381 10.21 IL18 IFNG IL2 IL10 FASLG NOD2
3 hematopoietic system MP:0005397 10.2 IL18 IFNG IL2 IL10 FASLG IL2RA
4 growth/size/body region MP:0005378 10.18 IL10 IL18 IFNG IL2 IL2RA NOD2
5 homeostasis/metabolism MP:0005376 10.17 FASLG IL18 IFNG IL2 IL10 NOD2
6 immune system MP:0005387 10.14 FASLG IL18 IFNG IL2 IL10 IL2RA
7 endocrine/exocrine gland MP:0005379 10.04 IL10 FASLG IFNG IL2RA TNF IL4
8 mortality/aging MP:0010768 10 IL10 FASLG IL18 IFNG IL2 IL2RA
9 integument MP:0010771 9.91 IL10 FASLG IL18 IFNG TNF IL4
10 liver/biliary system MP:0005370 9.87 IL10 FASLG IFNG IL2 TNF IL4
11 no phenotypic analysis MP:0003012 9.63 IL10 IFNG MYH9 TNF IL4 IL2
12 respiratory system MP:0005388 9.56 FASLG IFNG IL2 IL10 IL2RA TNF
13 vision/eye MP:0005391 9.28 FASLG IL18 IFNG IL2 IL10 IL2RA

Drugs & Therapeutics for Acute Graft Versus Host Disease

Drugs for Acute Graft Versus Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 332)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 104987-11-3 445643 439492
2
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 147-94-4 6253
3
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
5
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24280-93-1 446541
6
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 128794-94-5 5281078
7
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
8
Vidarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 24356-66-9 21704 32326
9
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 55-98-1 2478
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
11
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2 179045-86-4, 152923-56-3
12
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
13
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
14
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
15
Infliximab Approved Phase 4,Phase 2,Phase 1 170277-31-3
16
Daclizumab Approved, Investigational Phase 4,Phase 3 152923-56-3
17
Foscarnet Approved Phase 4 4428-95-9, 63585-09-1 3415
18
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
19
Menthol Approved Phase 4,Phase 1,Phase 2 2216-51-5 16666
20
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
21
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 58-05-9 143 6006
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59-30-3 6037
23
Treosulfan Investigational Phase 4,Phase 2 299-75-2 9296
24
Phosphonoacetic Acid Experimental Phase 4 4408-78-0 546
25
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
26 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
27 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Semustine Phase 4
29 Folic Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1
32 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
34 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Hormones Phase 4,Phase 3,Phase 2,Phase 1
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
38 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
39 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
43 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1
44 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
45 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
46 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
47 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
49 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
50 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 692)

# Name Status NCT ID Phase Drugs
1 ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
2 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
3 Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation Fro Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
4 Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT Completed NCT01232504 Phase 4 rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
5 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Recruiting NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
6 Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Recruiting NCT02677181 Phase 4 ATG;CsA;mycophenolate mofetil;Methotrexate
7 Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT Recruiting NCT02634294 Phase 4 Peg interferon alfa-2b
8 Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors Recruiting NCT02412423 Phase 4 post-transplantation cyclophosphamide
9 Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis Recruiting NCT01856803 Phase 4 anti thymoglobulin
10 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
11 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
12 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
13 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4 Busulfan;Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Tacrolimus;Methotrexate;Thymoglobulin;Basiliximab
14 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
15 A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT Not yet recruiting NCT03190733 Phase 4 ATG
16 Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation Not yet recruiting NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG(Sanofi/Genzyme)
17 Extracorporeal Photopheresis for Acute Graft Versus Host Disease Unknown status NCT00179855 Phase 2, Phase 3
18 MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis Unknown status NCT02270307 Phase 2, Phase 3 Cyclophosphamide
19 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
20 Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3 filgrastim
21 The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
22 The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease Completed NCT00726375 Phase 3 Etanercept (Enbrel)
23 Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease Completed NCT00035880 Phase 2, Phase 3 ABX-CBL
24 Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease Completed NCT00929695 Phase 3 prednisone;methylprednisolone
25 Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD Completed NCT00562497 Phase 3 Prochymal
26 Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease Completed NCT00366145 Phase 3
27 Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT) Completed NCT00655343 Phase 3 ATG-Fresenius S
28 Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease Completed NCT00053976 Phase 3 methylprednisolone;Placebo
29 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
30 Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation Completed NCT00130754 Phase 3 Thymoglobuline
31 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
32 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
33 Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease Completed NCT01788501 Phase 2, Phase 3 Tacrolimus;Cyclosporine;Methotrexate
34 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
35 Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation Completed NCT00002456 Phase 3 cyclosporine;methotrexate
36 Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation Completed NCT00993343 Phase 3 Sirolimus/tacrolimus;cyclosporine/methotrexate
37 Nonmyeloablative Stem Cell Transplant in Elderly Completed NCT00382759 Phase 2, Phase 3
38 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
39 Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
40 C-Reactive Protein as a Predictor of Stem Cell Transplant Complications Completed NCT00179868 Phase 2, Phase 3
41 Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy Completed NCT00469729 Phase 2, Phase 3 StemEx®
42 Stem Cell Transplant for Bone Marrow Failure Syndromes Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
43 Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA Completed NCT00455312 Phase 2, Phase 3 Campath 1H;Cyclophosphamide;Fludarabine;antithymocyte globulin;Methylprednisolone
44 Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Completed NCT00928018 Phase 3 Sirolimus;Methotrexate;Tacrolimus;Cyclosporine;MMF
45 Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Completed NCT00075816 Phase 3
46 Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) Completed NCT00412360 Phase 3 Cyclophosphamide;Fludarabine;Cyclosporine A;Mycophenolate Mofetil
47 Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies Completed NCT00275678 Phase 3
48 Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients Completed NCT00411645 Phase 3 maribavir
49 Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01237639 Phase 3
50 Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation Completed NCT01020175 Phase 3

Search NIH Clinical Center for Acute Graft Versus Host Disease

Genetic Tests for Acute Graft Versus Host Disease

Anatomical Context for Acute Graft Versus Host Disease

MalaCards organs/tissues related to Acute Graft Versus Host Disease:

38
T Cells, Bone, Bone Marrow, Myeloid, Nk Cells, Skin, Liver

Publications for Acute Graft Versus Host Disease

Articles related to Acute Graft Versus Host Disease:

(show top 50) (show all 754)
# Title Authors Year
1
Prediction of absolute risk of acute graft-versus-host disease following hematopoietic cell transplantation. ( 29346409 )
2018
2
Vedolizumab for treatment of steroid-refractory lower gastrointestinal acute graft-versus-host disease. ( 29371686 )
2018
3
Plasma vascular non-inflammatory molecule 3 is associated with gastrointestinal acute graft-versus-host disease in mice. ( 29311761 )
2018
4
Simple, Reproducible, and Efficient Clinical Grading System for Murine Models of Acute Graft-versus-Host Disease. ( 29403494 )
2018
5
Acute graft-versus-host disease following lung transplantation in a patient with a novel<i>TERT</i>mutation. ( 29382801 )
2018
6
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). ( 29379171 )
2018
7
Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival. ( 29391524 )
2018
8
Association analysis between SUFU polymorphism rs17114808 and acute graft versus host disease after hematopoietic stem cell transplantation. ( 29330404 )
2018
9
Acute Graft-versus-Host Disease. ( 29414273 )
2018
10
Acute Graft-versus-Host Disease. ( 29419277 )
2018
11
Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients. ( 29427741 )
2018
12
Mesenchymal stem cells transplantation in hematological patients with acute graft-versus-host disease: characteristics and risk factors for infectious complications. ( 29380038 )
2018
13
Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter? ( 29446444 )
2018
14
I+<sub>1</sub>-Antitrypsin Infusion for treatment of Steroid Resistant Acute Graft-versus-Host Disease. ( 29437593 )
2018
15
Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. ( 29345306 )
2018
16
CXCR3 blockade combined with cyclosporine A alleviates acute graft-versus-host disease by inhibiting alloreactive donor T cell responses in a murine model. ( 29288898 )
2018
17
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft versus host disease: low incidence of lower gastrointestinal tract disease. ( 29351985 )
2018
18
Predicting death in patients with acute graft-versus-host disease after reduced-intensity conditioning. ( 28863797 )
2017
19
The association between acute graft-versus-host disease and antimicrobial peptide expression in the gastrointestinal tract after allogeneic stem cell transplantation. ( 28934349 )
2017
20
Cutaneous acute graft-versus-host disease with isomorphic disposition over striae distensae in a 12-year-old girl. ( 27805255 )
2017
21
Is It Time to Reconsider the Lipopolysaccharide Paradigm in Acute Graft-Versus-Host Disease? ( 28848554 )
2017
22
Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. ( 28088653 )
2017
23
Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. ( 28423578 )
2017
24
Acute Graft-Versus-Host Disease Prognosis: Are Biomarkers Ready for Preemptive Clinical Trials? ( 28687636 )
2017
25
Peripheral blood Th9 cells reconstitution and its relationship with acute graft-versus-host disease after matched-sibling peripheral blood hematopoietic stem cell transplantation. ( 28861153 )
2017
26
Changes in body composition in children with acute graft-versus-host disease within the first 100 days after hematopoietic stem cell transplantation. ( 29269889 )
2017
27
Bridging-to-transplant with Azacitidine for Myelodysplastic Syndrome and Acute Myeloid Leukemia, Reduces the Incidence of Acute Graft-versus-host Disease. ( 28670436 )
2017
28
Protection of Mice from Acute Graft-versus-Host Disease Requires CD28 Co-stimulation on Donor CD4(+) Foxp3(+) Regulatory T Cells. ( 28690612 )
2017
29
Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. ( 29269797 )
2017
30
Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. ( 28159900 )
2017
31
Acute graft-versus-host disease of the gut: considerations for the gastroenterologist. ( 28951581 )
2017
32
The Effect of CCR5I932 on the Risk of Grade 3-4 Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. ( 28862353 )
2017
33
Evaluation of Serum Interleukin-21 and HLA-C1 Polymorphism in Pediatrician Hematopoietic Stem Cell Transplantation for Early Diagnosis of Acute Graft-Versus-Host Disease ( 28627158 )
2017
34
Chitinase 3-Like-1-Deficient Splenocytes Deteriorated the Pathogenesis of Acute Graft-Versus-Host Disease via Regulating Differentiation of Tfh Cells. ( 28656528 )
2017
35
Lessons Learned from Early Experiences with Vedolizumab for Steroid-Refractory Acute Graft- versus-Host Disease with Gastrointestinal Involvement. ( 28578009 )
2017
36
Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. ( 27766393 )
2017
37
OSI-027 modulates acute graft-versus-host disease after liver transplantation in a rat model. ( 28590550 )
2017
38
Correction: Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. ( 28938702 )
2017
39
Systemic Treatment with a miR-146a Mimic Suppresses Endotoxin Sensitivity and Partially Protects Mice from the Progression of Acute Graft-versus-Host Disease. ( 28853768 )
2017
40
Fecal microbiota transplantation for acute graft-versus-host disease of the gut. ( 28592766 )
2017
41
Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease? ( 28671556 )
2017
42
EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. ( 28733186 )
2017
43
The Combination of Cyclosporine and Mycophenolate Mofetil is Less Effective than Cyclosporine and Methotrexate in the Prevention of Acute Graft-versus Host Disease after Stem-cell Transplantation from Unrelated Donors. ( 28052467 )
2017
44
A20 deletion in TA cells modulates acute graft-versus-host disease in mice. ( 28833031 )
2017
45
Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation. ( 29269806 )
2017
46
Chitinase 3-like-1 deficient donor splenocytes accentuated the pathogenesis of acute graft-versus-host diseases through regulating T cell expansion and type I inflammation. ( 28324830 )
2017
47
Dynamics of M1 macrophages in oral mucosal lesions during the development of acute graft-versus-host disease in rats. ( 28862740 )
2017
48
Evaluation of interleukin 12 and CD56+ lymphocyte cells in pediatric hematopoietic stem cell transplantation for early diagnosis of acute graft versus host disease. ( 27751764 )
2016
49
High expression of heme oxygenase-1 in target organs may attenuate acute graft-versus-host disease through regulation of immune balance of TH17/Treg. ( 27168057 )
2016
50
A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. ( 27498124 )
2016

Variations for Acute Graft Versus Host Disease

Expression for Acute Graft Versus Host Disease

Search GEO for disease gene expression data for Acute Graft Versus Host Disease.

Pathways for Acute Graft Versus Host Disease

Pathways related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 ARHGAP45 FASLG IFNG IL10 IL18 IL2
2
Show member pathways
13.81 FASLG IL10 IL18 IL2 IL2RA IL4
3
Show member pathways
13.65 FASLG IFNG IL10 IL18 IL2 IL2RA
4
Show member pathways
13.5 IFNG IL10 IL18 IL2 IL2RA IL4
5
Show member pathways
13.42 FASLG IL10 IL18 IL2 IL2RA IL4
6
Show member pathways
13.36 FASLG IFNG IL10 IL18 IL2 IL2RA
7
Show member pathways
13.3 FASLG IL10 IL18 IL2 IL2RA IL4
8
Show member pathways
12.95 FASLG IL2 IL2RA IL4 TNF
9
Show member pathways
12.88 FASLG GZMB IFNG IL10 IL2 IL2RA
10
Show member pathways
12.85 FASLG IFNG IL18 IL2 IL2RA IL4
11 12.83 FASLG IFNG IL2 IL2RA IL4
12
Show member pathways
12.68 IFNG IL10 IL18 IL2 IL2RA IL4
13
Show member pathways
12.62 IFNG IL10 IL18 IL2 TNF
14
Show member pathways
12.6 IFNG IL10 IL18 IL2 IL2RA IL4
15
Show member pathways
12.59 FASLG GZMB IFNG IL2 IL4 TNF
16
Show member pathways
12.57 FASLG IFNG IL10 IL2 TNF
17
Show member pathways
12.48 IFNG IL10 IL2 IL4 TNF
18
Show member pathways
12.43 IFNG IL10 IL2 IL2RA IL4
19 12.42 FASLG GZMB IFNG IL10 IL2 IL2RA
20
Show member pathways
12.34 IFNG IL2 IL4 TNF
21 12.3 IFNG IL10 IL18 NOD2 TNF
22
Show member pathways
12.28 IFNG IL10 IL4 TNF
23
Show member pathways
12.21 FASLG IFNG IL4 TNF
24
Show member pathways
12.21 IFNG IL10 IL18 IL2 IL4 TNF
25 12.08 FASLG IL10 IL18 IL4 TNF
26 12.06 IFNG IL2 IL4 TNF
27 12.05 IFNG IL10 IL2 IL2RA IL4 TNF
28
Show member pathways
12.03 IFNG IL2 IL2RA
29
Show member pathways
12.01 IFNG IL10 IL18 IL2 TNF
30
Show member pathways
11.97 FASLG GZMB IFNG IL18 IL2 IL2RA
31 11.9 IFNG IL10 IL2 IL2RA
32 11.89 IL2RA IL4 TNF
33 11.88 IFNG IL10 TNF
34
Show member pathways
11.86 GZMB IFNG IL4
35 11.85 IFNG IL18 TNF
36 11.83 IFNG IL18 MYH9
37 11.83 IFNG IL10 IL2 TNF
38 11.8 IFNG IL2 IL4
39
Show member pathways
11.8 FASLG TNF TNFRSF4
40
Show member pathways
11.79 FASLG IL2 IL2RA IL4
41 11.78 IL10 IL2RA IL4 TNF TNFRSF4
42
Show member pathways
11.76 FASLG IFNG IL2 IL2RA IL4 TNF
43
Show member pathways
11.68 IFNG IL2 TNF
44 11.66 FASLG IFNG IL2 TNF
45 11.63 IL10 IL18 IL4 TNF
46 11.63 IFNG IL10 IL18 TNF
47 11.56 IFNG IL2 TNF
48 11.56 IFNG IL18 TNF
49 11.52 FASLG IFNG TNF
50
Show member pathways
11.49 FASLG GZMB IFNG IL2 IL2RA TNF

GO Terms for Acute Graft Versus Host Disease

Cellular components related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 FASLG IFNG IL10 IL18 IL2 IL4
2 cell surface GO:0009986 9.35 FASLG IL2RA NOD2 TNF TNFRSF4
3 extracellular region GO:0005576 9.23 ARHGAP45 FASLG IFNG IL10 IL18 IL2

Biological processes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.95 FASLG IL10 IL18 IL2
2 MAPK cascade GO:0000165 9.94 IL18 IL2 IL2RA TNF
3 inflammatory response GO:0006954 9.91 IL10 IL18 IL2RA TNF TNFRSF4
4 tumor necrosis factor-mediated signaling pathway GO:0033209 9.85 FASLG TNF TNFRSF4
5 negative regulation of inflammatory response GO:0050728 9.82 IL10 IL2 IL2RA
6 cellular response to organic cyclic compound GO:0071407 9.8 IL18 NOD2 TNF
7 apoptotic signaling pathway GO:0097190 9.79 FASLG TNF TNFRSF4
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.78 IFNG IL18 IL2
9 positive regulation of T cell proliferation GO:0042102 9.74 IL2 IL2RA IL4
10 positive regulation of interferon-gamma production GO:0032729 9.72 IL18 IL2 TNF
11 extrinsic apoptotic signaling pathway GO:0097191 9.71 FASLG IFNG TNF
12 positive regulation of B cell proliferation GO:0030890 9.7 IL2 IL4 TNFRSF4
13 negative regulation of myoblast differentiation GO:0045662 9.69 IL18 TNF
14 positive regulation of NF-kappaB import into nucleus GO:0042346 9.68 IL18 TNF
15 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.68 IL10 TNF
16 natural killer cell activation GO:0030101 9.68 IL18 IL2
17 positive regulation of osteoclast differentiation GO:0045672 9.68 IFNG TNF
18 natural killer cell mediated cytotoxicity GO:0042267 9.67 GZMB IL18
19 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.67 IFNG TNF
20 negative regulation of growth of symbiont in host GO:0044130 9.66 IL10 TNF
21 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.66 IL10 TNF
22 positive regulation of immunoglobulin secretion GO:0051024 9.65 IL2 TNFRSF4
23 positive regulation of isotype switching to IgG isotypes GO:0048304 9.64 IL2 IL4
24 endothelial cell apoptotic process GO:0072577 9.63 IL10 TNF
25 positive regulation of MHC class II biosynthetic process GO:0045348 9.61 IL10 IL4
26 negative regulation of lymphocyte proliferation GO:0050672 9.6 IL2 IL2RA
27 necroptotic signaling pathway GO:0097527 9.59 FASLG TNF
28 negative regulation of cytokine secretion involved in immune response GO:0002740 9.58 IL10 TNF
29 positive regulation of tissue remodeling GO:0034105 9.58 IL18 IL2
30 positive regulation of activated T cell proliferation GO:0042104 9.58 IL18 IL2 IL2RA
31 regulation of isotype switching GO:0045191 9.56 IL10 IL4
32 positive regulation of T cell differentiation GO:0045582 9.54 IL2 IL2RA IL4
33 regulation of regulatory T cell differentiation GO:0045589 9.5 IFNG IL2 IL2RA
34 regulation of receptor activity GO:0010469 9.5 FASLG IFNG IL10 IL18 IL2 IL4
35 receptor biosynthetic process GO:0032800 9.49 IL10 TNF
36 regulation of T cell homeostatic proliferation GO:0046013 9.48 IL2 IL2RA
37 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.46 IFNG TNF
38 positive regulation of vitamin D biosynthetic process GO:0060557 9.43 IFNG TNF
39 positive regulation of interleukin-17 production GO:0032740 9.43 IL18 IL2 NOD2
40 type 2 immune response GO:0042092 9.33 IL10 IL18 IL4
41 immune response GO:0006955 9.28 FASLG IFNG IL10 IL18 IL2 IL2RA
42 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 IL10 IL18 IL2 IL4 NOD2 TNF

Molecular functions related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.77 ARHGAP45 FASLG GZMB IFNG IL10 IL18
2 cytokine activity GO:0005125 9.17 FASLG IFNG IL10 IL18 IL2 IL4

Sources for Acute Graft Versus Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....